SEC Tracker
Get the app

Spyre Therapeutics SYRE

Spyre Therapeutics offers common stock

Securities offering

Form
424B5
Filed
Importance
Routine
  1. Offering shares of common stock
  2. Public offering price not specified
  3. Underwriters can buy additional shares within 30 days
  4. Company has $1.1 billion in cash as of June 30, 2026

Written from the 424B5 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Spyre Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  2. Mannkind MNKD public float $1.1B, Jun 30, 2025
  3. Novavax NVAX public float $1.0B, Jun 30, 2025
  4. Harrow HROW public float $1.0B, Jun 30, 2025
  5. Aurinia Pharmaceuticals AUPH public float $1.0B, Jun 30, 2025